Rxivist logo

Mitochondriomics reveals the underlying neuoprotective mechanism of TrkB receptor agonist R13 in the 5xFAD mice

By Xiao Li, Ting Li, Yongmei Xie, Zaijun Zhang, Jianjun Liu, Hao Yu, Shupeng Li, Xiangrong Song, Xifei Yang, Gongping Liu

Posted 08 Feb 2021
bioRxiv DOI: 10.1101/2021.02.08.430227

Decreased energy metabolism and mitochondrial biogenesis defects are implicated in the pathogenesis of Alzheimer's disease (AD). In present study, mitochondriomics analysis revealed significant effects of R13, a prodrug of 7,8-dihydroxyflavone, on mitochondrial protein expression profile, including the proteins related to the biological processes: fatty acid beta-oxidation, fatty acid metabolic process, mitochondrial electron transport, and mitochondrial respiratory chain. Cluster analysis of mitochondriomics demonstrated that R13 promoted mitochondrial oxidative phosphorylation (OXPHOS). The functional analysis showed that R13 increased ATP levels and enhanced OXPHOS including complex I, complex II, complex III and complex IV. R13 treatment increased mitochondrial biogenesis by regulating the levels of p-AMPK, p-CREB, PGC-1, NRF1 and TFAM as a consequence of activation of TrkB receptor in the 5xFAD mice. Finally, R13 significantly reduced the levels of tau phosphorylation and A{beta} plaque. Our data suggest that R13 may be used for treating AD via enhancing mitochondrial biogenesis and metabolism.

Download data

  • Downloaded 104 times
  • Download rankings, all-time:
    • Site-wide: 131,337
    • In pharmacology and toxicology: 1,130
  • Year to date:
    • Site-wide: 34,787
  • Since beginning of last month:
    • Site-wide: 37,379

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide